| Literature DB >> 36009925 |
Zia Ul Mustafa1,2, Amer Hayat Khan1, Muhammad Salman3, Syed Azhar Syed Sulaiman1, Brian Godman4,5,6.
Abstract
Antimicrobial resistance (AMR) compromises global health due to the associated morbidity, mortality, and costs. The inappropriate use of antimicrobial agents is a prime driver of AMR. Consequently, it is imperative to gain a greater understanding of current utilization patterns especially in high-risk groups including neonates and children. A point prevalence survey (PPS) was conducted among three tertiary care children's hospitals in the Punjab province using the World Health Organization (WHO) methodology. Antibiotic use was documented according to the WHO AWaRe classification. Out of a total of 1576 neonates and children, 1506 were prescribed antibiotics on the day of the survey (prevalence = 95.5%), with an average of 1.9 antibiotics per patient. The majority of antibiotics were prescribed in the medical ward (75%), followed by surgical ward (12.8%). Furthermore, 56% of antibiotics were prescribed prophylactically, with most of the antibiotics (92.3%) administered via the parenteral route. The top three indications for antibiotics were respiratory tract infections (34.8%), gastrointestinal infections (15.8%), and prophylaxis for medical problems (14.3%). The three most common antibiotics prescribed were ceftriaxone (25.8%), amikacin (9.2%), and vancomycin (7.9%). Overall, 76.6% of the prescribed antibiotics were from Watch category followed by 21.6% from the Access group. There was a very high prevalence of antibiotic use among hospitalized neonates and children in this study. Urgent measures are needed to engage all the stakeholders to formulate effective ASPs in Pakistan, especially surrounding Watch antibiotics.Entities:
Keywords: AWaRe classification; Pakistan; antibiotics; children; hospitals; point prevalence survey
Year: 2022 PMID: 36009925 PMCID: PMC9405424 DOI: 10.3390/antibiotics11081056
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Hospital, ward, patient, and antibiotics prevalence related information.
| Variables N (%) | H1 | H2 | H3 | Total N (%) |
|---|---|---|---|---|
| Total bed in hospital | 1050 | 570 | 250 | 1870 |
| Total bed in children ward | 1010 | 510 | 170 | 1690 |
| Total patients in children ward at 8:00 AM | 987 | 464 | 125 | 1576 (93.2) |
| Total No. of patients prescribed antibiotics and % | 936 (94.8) | 461 (99.4%) | 109 (87.2%) | 1506 (95.5) |
|
| ||||
| Neonates (0–28 days) | 136 (14.5) | 142 (30.8) | 8 (7.3) | 286 (19.0) |
| Infants (29 days–1 year) | 337 (36.0) | 83 (18.0) | 42 (38.5) | 462 (30.7) |
| Young child (˃1–5 years) | 252 (26.9) | 113 (24.5) | 26 (23.8) | 391 (25.9) |
| Child (˃5–12 years) | 211 (22.6) | 123 (26.6) | 33 (30.3) | 367 (24.3) |
| Total no. of prescribed antibiotics and per patient | 1534 (1.64) | 1151 (2.50) | 174 (1.60) | 2859 (1.90) |
|
| ||||
| One antibiotic | 354 (23.0) | 156 (13.5) | 51 (29.3) | 561 (19.6) |
| Two antibiotics | 1032 (67.3) | 572 (49.7) | 108 (62.0) | 1712 (59.9) |
| Three antibiotics or above | 148 (9.7) | 423 (36.8) | 15 (8.7) | 586 (20.4) |
|
| ||||
| Antiviral | 52 (32.0) | 23 (53.5) | 03 (60.0) | 78 (2.5) |
| Antifungal | 79 (48.8) | 04 (9.3) | 01 (20.0) | 84 (2.7) |
| Antiprotozoal | 31 (19.2) | 16 (37.2) | 01 (20.0) | 48 (1.5) |
|
| ||||
| Male | 526 (56.2) | 174 (37.8) | 64 (58.7) | 764 (50.7) |
| Female | 410 (43.8) | 287 (62.2) | 45 (41.3) | 742 (49.3) |
|
| ||||
| Oral | 164 (10.7) | 45 (4.0) | 13 (7.5) | 222 (7.7) |
| Parenteral | 1370 (89.3) | 1106 (96.0) | 161 ((92.5) | 2637 (92.3) |
|
| ||||
| Medical | 1267 (82.6) | 752 (65.3) | 126 (72.4) | 2145 (75.0) |
| Surgical | 175 (11.4) | 156 (13.6) | 36 (20.6) | 367 (12.8) |
| ICU | 92 (5.9) | 243 (21.1) | 12 (6.9) | 347 (12.2) |
|
| ||||
| Therapeutic use | 962 (62.7) | 571 (49.6) | 94 (54.0) | 1627 (56.9) |
| Prophylaxis use | 356 (23.2) | 468 (40.6) | 63 (36.2) | 887 (31.0) |
| Unknown | 216 (14.1) | 112 (9.8) | 17 (9.8) | 345 12.1) |
|
| ||||
| Medical | 257 (72.2) | 327 (69.9) | 36 (57.1) | 620 (69.9) |
| Surgical | 99 (27.8) | 141 (30.1) | 27 (42.9) | 267 (31.1) |
|
| ||||
| Single dose | 31 (31.3) | 0 | 0 | 31 (11.6) |
| One day | 17 (17.2) | 07 (4.9) | 04 (14.8) | 28 (10.4) |
| More than one day | 51 (51.5) | 134 (95.0) | 23 (85.2) | 208 (77.9) |
|
| ||||
| Community acquired | 1457 (94.9) | 1113 (96.7) | 152 (87.3) | 2722 (95.2) |
| Hospital acquired | 77 (5.0) | 38 (3.3) | 22 (12.7) | 137 (4.8) |
|
| ||||
| No | 1387 (90.4) | 1097 (95.3) | 171 (98.2) | 2655 (92.9) |
| Yes | 147 (9.6) | 54 (4.7) | 03 (1.7) | 204 (7.1) |
|
| ||||
| Yes | 573 (37.3) | 237 (20.6) | 41 (23.5) | 851 (29.7) |
| No | 961 (62.7) | 914 (79.4) | 133 (76.4) | 2008 (70.3) |
|
| ||||
| Empirical therapy | 1480 (96.5) | 1118 (97.1) | 165 (94.8) | 2763 (96.6) |
| Targeted therapy | 54 (3.5) | 33 (2.9) | 09 (5.1) | 96 (3.4) |
Details of prescribed antibiotics according to age groups.
| Variables N (%) | Neonates | Infants | Young Child | Child |
|---|---|---|---|---|
|
| 569 (1.99) | 852 (1.84) | 771 (1.97) | 667 (1.82) |
|
| ||||
| Medical | 436 (76.6) | 678 (79.6) | 565 (73.3) | 466 (69.8) |
| Surgical | 5 (0.9) | 68 (8.0) | 136 (17.6) | 158 (23.7) |
| ICU | 128 (22.5) | 106 (12.4) | 70(9.0) | 43 (6.4) |
|
| ||||
| Therapeutic use | 409 (71.9) | 612 (71.8) | 406 (52.6) | 200 (30.0) |
| Prophylaxis use | 118 (20.7) | 178 (20.9) | 281 (36.4) | 310 (46.5) |
| Unknown | 42 (7.4) | 62 (7.2) | 84 (10.9) | 157 (23.5) |
|
| ||||
| Medical | 113 (95.7) | 130 (73.0) | 185 (65.9) | 192 (61.9) |
| Surgical | 5 (4.2) | 48 (27.0) | 96 (34.1) | 118 (38.0) |
|
| ||||
| Single dose | 1 (20.0) | 7 (14.6) | 14 (14.6) | 09 (7.6) |
| One day | 1 (20.0) | 08 (16.7) | 16 (16.6) | 03 (2.5) |
| More one day | 3 (60.0) | 33 (3368.7) | 66 (68.8) | 106 (89.8) |
|
| ||||
| Community acquired | 560 (98.4) | 826 (97.0) | 734 (95.2) | 602 (90.2) |
| Hospital acquired | 09 (1.6) | 26 (3.0) | 37 (4.8) | 65 (9.8) |
|
| ||||
| No | 508 (89.3) | 824 (96.7) | 718 (93.1) | 605 (90.7) |
| Yes | 61 (10.7) | 28 (3.3) | 53 (6.9) | 62 (9.3) |
|
| ||||
| Yes | 213 (37.4) | 191 (22.4) | 153 (19.9) | 294 (44.0) |
| No | 356 (62.6) | 661 (77.6) | 618 (80.1) | 373 (56.0) |
|
| ||||
| Empirical therapy | 556 (97.7) | 811 (95.1) | 744 (96.5) | 652 (97.7) |
| Targeted therapy | 13 (2.3) | 41 (4.8) | 27 (3.5) | 15 (2.2) |
Antibiotic resistance and antibiotic susceptibility profiles of commonly identified bacterial species.
| Common Identified Bacteria | Common Resistant Antibiotics | Common Sensitive Antibiotics | H1 | H2 | H3 | Total N (%) |
|---|---|---|---|---|---|---|
| Ampicillin, amoxicillin, ciprofloxacin, levofloxacin, | Vancomycin, linezolid | 24 | 05 | - | 29 (30.2) | |
| Penicillins, | Levofloxacin, cefepime | 11 | 10 | - | 21 (21.9) | |
| 3rd generation cephalosporins such as cefotaxime, ceftriaxone | Cephoperazone + beta-lactamase inhibitor, | 04 | 11 | 05 | 20 (20.9) | |
|
| Penicillin, amoxicillin | Carbapenems such as meropenem, imipenem | 11 | - | 04 | 15 (15.7) |
| Ampicillin, amoxicillin | Ceftriaxone, ciprofloxacin | 05 | 05 (5.2) | |||
| Others | - | - | 04 | 02 | - | 06 (6.2) |
Indications for prescribed antibiotics among the study participants.
| Infection Type | H1 (%) | H2 (%) | H3 (%) | Total N (%) |
|---|---|---|---|---|
| Respiratory tract infections | 346 (66.0) | 147 (28.0) | 31 (5.9) | 524 (34.8) |
| Gastrointestinal infections | 152 (63.9) | 69 (28.9) | 17 (7.1) | 238 (15.8) |
| Prophylaxis for medical problems | 116 (53.7) | 87 (40.2) | 13 (6.0) | 216 (14.3) |
| Prophylaxis for surgical diseases | 96 (62.3) | 42 (27.3) | 16 (10.4) | 154 (10.2) |
| Blood stream infection | 48 (51.6) | 36 (38.7) | 09 (9.6) | 93 (6.1) |
| Skin and soft tissue infections | 57 (63.3) | 27 (30.0) | 06 (6.6) | 90 (6.0) |
| Sepsis | 46 (54.1) | 23 (27.0) | 16 (18.8) | 85 (5.6) |
| Urinary tract infections | 48 (71.6) | 19 (28.3) | 0 | 67 (4.4) |
| Others | 27 (69.2) | 11 (28.2) | 01 (2.5) | 39 (2.6) |
NB: Medical problems indicated dyspepsia, anemia, cystic fibrosis, and autoimmune diseases.
Indications for prescribed antibiotics according to age groups.
| Variables N (%) | Neonates (%) | Infants (%) | Young Child (%) | Child (%) |
|---|---|---|---|---|
| Respiratory tract infections | 138 (26.3) | 211 (40.2) | 103 (19.6) | 72 (13.7) |
| Gastrointestinal infections | 89 (37.4) | 52 (21.8) | 28 (11.7) | 69 (29.0) |
| Prophylaxis for medical problems | 41 (19.0) | 83 (38.4) | 47 (21.7) | 45 (20.8) |
| Prophylaxis for surgical diseases | 05 (3.2) | 64 (41.5) | 37 (24.0) | 48 (31.1) |
| Blood stream infection | 12 (12.9) | 11 (11.8) | 42 (45.1) | 31 (33.3) |
| Skin and soft tissue infections | 09 (10.0) | 23 (25.5) | 18 (20.0) | 40 (44.4) |
| Sepsis | 37 (43.5) | 14 (60.8) | 23 (27.0) | 11 (12.9) |
| Urinary tract infections | 09 (13.4) | 14 (20.9) | 27 (40.3) | 17 (25.4) |
| Others | 13 (33.3) | 08 (20.5) | 06 (15.4) | 12 (30.7) |
NB: %s in each column equate to the %s for each indication by age group.
Detail of prescribed antibiotics according to ATC classification.
| ATC class | Name of Antibiotics (ATC code) | H1 | H2 | H3 | Total (%) |
|---|---|---|---|---|---|
| Third-generation cephalosporin | Ceftriaxone (J01DD04) | 419 | 277 | 44 | 740 (25.8) |
| Cefotaxime (J01DD01) | 119 | 83 | 28 | 230 (8.0) | |
| Ceftazidime (J01DD02) | 23 | 31 | 13 | 67 (2.3) | |
| Cefixime (J01DD08) | 27 | - | - | 27 (0.9) | |
| Cephoperazone + beta-lactamase inhibitor (salbactam) (J01DD12) | 20 | 73 | 14 | 107 (3.7) | |
| Aminoglycoside | Amikacin (D06AX12) | 13 | 112 | 21 | 264 (9.2) |
| Glycopeptide antibacterials | Vancomycin (J01XA01) | 177 | 46 | 05 | 228 (7.9) |
| Macrolides | Azithromycin (J01FA10) | 53 | 69 | 03 | 125(4.3) |
| Clarithromycin (J01FA09) | 24 | 27 | 07 | 58 (2.0) | |
| Piperacillin and enzyme inhibitor | Piperacillin + enzyme inhibitor (tazobactam) | 89 | 71 | 11 | 171 (5.9) |
| Aminopenicillins | Ampicillin (J01CA01) | 64 | 82 | 02 | 148 (5.1) |
| Amoxicillin and beta-lactamase inhibitor | Amoxicillin + beta-lactamase inhibitors (clavulanate) (J01CR02) | 74 | 56 | - | 130 (4.5) |
| Carbapenems | Meropenem (J01DH02) | 49 | 57 | 12 | 118 (4.1) |
| Imipenem and cilastatin (J01DH51) | 09 | 04 | - | 13 (0.4) | |
| Fluoroquinolones | Ciprofloxacin (J01MA02) | 63 | 43 | 04 | 110 (3.8) |
| Moxifloxacin (J01MA14) | 14 | 03 | - | 17 (0.5) | |
| Imidazole derivatives | Metronidazole (J01XD01) | 58 | 26 | 02 | 86 (3.0) |
| Fourth-generation cephalosporins | Cefepime (J01DE01) | 53 | 30 | 04 | 87 (3.0) |
| Penicillins with extended spectrum | Amoxicillin (J01CA04) | 13 | 37 | 04 | 54 (1.8) |
| Other antibacterials | Linezolid (J01XX08) | 33 | 17 | - | 50 (1.7) |
| First generation cephalosporins | Cefradine | 11 | - | - | 11 (0.3) |
| Others | - | 11 | 07 | - | 18 (0.6) |
Detail of prescribed antibiotics according two WHO AwaRe classification.
| AwaRe Category | H1 | H2 | H3 | Total N (%) |
|---|---|---|---|---|
| Access | 305 | 287 | 27 | 619 (21.7) |
| Watch | 1196 | 847 | 147 | 2190 (76.6) |
| Reserve | 33 | 17 | 0 | 50 (1.7) |
Figure 1Antibiotics use according to WHO AWaRe classification.